Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $218,216.46 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Price Performance

NASDAQ:TBPH opened at $16.58 on Friday. Theravance Biopharma, Inc. has a 52 week low of $10.44 and a 52 week high of $21.03. The stock has a market capitalization of $854.75 million, a PE ratio of 7.54 and a beta of 0.17. The stock’s 50-day moving average price is $16.50 and its 200-day moving average price is $17.36.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. Sell-side analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. BTIG Research reiterated a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research report on Friday, March 20th. TD Cowen upped their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. Weiss Ratings downgraded shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 27th. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. Finally, Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $21.40.

Institutional Trading of Theravance Biopharma

A number of institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Theravance Biopharma by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the last quarter. Creative Planning grew its stake in Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 842 shares in the last quarter. State of Wyoming grew its stake in Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 1,020 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.